Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.08 USD

41.08
69,282

-0.10 (-0.24%)

Updated Aug 14, 2024 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mark Vickery headshot

Top Research Reports for Pfizer, Coca-Cola & Adobe

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Coca-Cola Company (KO) and Adobe Inc. (ADBE).

Immunome (IMNM) COVID-19 Cocktail Hold Lifted, Shares Gain

by Zacks Equity Research

Immunome (IMNM) gains as FDA lifts clinical hold on its Investigational New Drug (IND) application for its antibody cocktail (IMM-BCP-01) for the treatment of COVID-19.

AstraZeneca, Merck's Lynparza Gets FDA Nod for Expanded Use

by Zacks Equity Research

FDA approves AstraZeneca (AZN) and Merck's (MRK) Lynparza for BRCA-mutated HER2-negative high-risk early breast cancer.

GlaxoSmithKline (GSK) Stock Moves -0.66%: What You Should Know

by Zacks Equity Research

In the latest trading session, GlaxoSmithKline (GSK) closed at $40.56, marking a -0.66% move from the previous day.

GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed the most recent trading day at $40.83, moving -1.23% from the previous trading session.

AstraZeneca (AZN), Sanofi's (SNY) RSV Vaccine Lowers Infections

by Zacks Equity Research

AstraZeneca (AZN) and Sanofi's (SNY) nirsevimab reduces lower respiratory tract infections like bronchiolitis or pneumonia caused by RSV 74.5% in infants.

GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

GlaxoSmithKline (GSK) closed the most recent trading day at $41.45, moving -1.38% from the previous trading session.

SAB (SABS) Abandons COVID-19 Treatment Study, Stock Plummets

by Zacks Equity Research

Low hospitalization rates force SAB Biotherapeutics (SABS) to discontinue the late-stage study that is evaluating its COVID-19 antibody treatment. Stock down almost 40% post the announcement.

Pfizer (PFE) Gets Breakthrough Therapy Status for RSV Vaccine

by Zacks Equity Research

Pfizer (PFE) is developing an RSV vaccine candidate, RSVpreF, to immunize pregnant women or older adults. The FDA grants a breakthrough therapy tag for the candidate's use in pregnant women.

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

by Zacks Equity Research

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Debanjana Dey headshot

Allscripts' (MDRX) Q4 Earnings Beat Estimates, Margins Up

by Debanjana Dey

Allscripts' (MDRX) robust Q4 results demonstrate strength in both segments.

Kinjel Shah headshot

Pharma Stock Roundup: GSK, SNY Face Pipeline Setbacks, AZN Cancer Study Meets Goals

by Kinjel Shah

Glaxo (GSK) and Sanofi (SNY) announce pipeline setbacks. AstraZeneca's (AZN) HER2-low metastatic breast cancer study on Enhertu succeeds.

Chemed (CHE) Q4 Earnings Surpass Estimates, Revenues Miss

by Zacks Equity Research

Chemed (CHE) reports better-than-expected earnings for the fourth quarter, with a robust performance by the Roto-Rooter arm driving the top line.

Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up

by Zacks Equity Research

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.

Nevro's (NVRO) Q4 Earnings in Line, Revenues Beat Estimates

by Zacks Equity Research

Nevro's (NVRO) worldwide revenues fall on a year-over-year basis in Q4 due to soft geographical performances.

Avanos Medical (AVNS) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research

Avanos Medical's (AVNS) fourth-quarter 2021 results gain from strength in the chronic care segment.

Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.

Mark Vickery headshot

Top Analyst Reports for Amazon, Home Depot & PetroChina

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Home Depot, Inc. (HD), and PetroChina Company Limited (PTR).

Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.

AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer

by Zacks Equity Research

AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.

Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock Down

by Zacks Equity Research

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.

AstraZeneca's (AZN) Lupus Drug Saphnelo Gets Europe Nod

by Zacks Equity Research

AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus.

Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results reflect robust performance across six of its business units.

West Pharmaceutical (WST) Q4 Earnings & Revenues Top Estimates

by Zacks Equity Research

West Pharmaceutical's (WST) fourth-quarter earnings reflect strength in the Proprietary Products segment and margin expansion.

GSK vs. LLY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GSK vs. LLY: Which Stock Is the Better Value Option?